Minutes: 8th Drug Safety Review Session, FY2026
Overview
At the September 29, 2026 review session, the proposed revision to the Precautions for Use of tacrolimus hydrate ointment was discussed and approved without objection. The contraindications for the 0.03% pediatric formulation will be revised to allow use in children aged 6 months to under 2 years, with a maximum amount of 0.5 g per application. Efficacy was confirmed in a clinical trial, and no new safety concerns were identified.
Key points
- The review session approved the revision as proposed by the secretariat without objection.
- Efficacy was confirmed in a post-marketing clinical trial, and no new safety concerns were identified.
- By September 2, 2026, adverse reaction reports included 3 cases and 4 events in children under 2 years; all were events considered known from the package insert.
Overview
The agenda was revision of the Precautions for Use of tacrolimus hydrate ointment. The review of contraindications considered results from a post-marketing clinical trial in children under 2 years, domestic and international reports on use experience, and opinions submitted by academic societies.
Impact
The expert stated that allowing tacrolimus ointment to be used in children aged 6 months to under 2 years benefits patients and helps with treatment.
Details
For the 0.03% pediatric formulation, “children under 2 years” will be removed from the contraindications and replaced with “infants under 6 months.” The precautions related to dosage and administration will specify a maximum amount per application for children aged 6 months to under 2 years, and the “Pediatric Use” section will also be revised to state that the product should not be used in infants under 6 months.
The electronic package insert for the same formulation will be updated with pharmacokinetic and clinical results from a post-marketing clinical trial in children aged 6 months to under 2 years. The “Pediatric Use” section for the 0.1% formulation will state that no clinical trials have been conducted in infants under 6 months and similar patients.
The review session approved the proposed revision, and the secretariat said it would instruct the marketing authorization holder to make the revision. The warning in the package insert requiring use under the supervision of a physician experienced in treating pediatric atopic dermatitis will remain in effect. The company said it plans to prepare materials reflecting the revision.